BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29946154)

  • 21. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.
    Hamulyák EN; Daams JG; Leebeek FWG; Biemond BJ; Te Boekhorst PAW; Middeldorp S; Lauw MN
    Blood Adv; 2021 Jan; 5(1):113-121. PubMed ID: 33570633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical approach to splanchnic vein thrombosis: risk factors and treatment.
    Riva N; Donadini MP; Dentali F; Squizzato A; Ageno W
    Thromb Res; 2012 Oct; 130 Suppl 1():S1-3. PubMed ID: 23026649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
    Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
    Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease.
    Amitrano L; Guardascione MA; Ames PR; Margaglione M; Antinolfi I; Iannaccone L; Annunziata M; Ferrara F; Brancaccio V; Balzano A
    Am J Hematol; 2003 Feb; 72(2):75-81. PubMed ID: 12555209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
    Koschmieder S
    Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
    Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
    Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms.
    Hoekstra J; Bresser EL; Smalberg JH; Spaander MC; Leebeek FW; Janssen HL
    J Thromb Haemost; 2011 Nov; 9(11):2208-14. PubMed ID: 22040061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.
    De Stefano V; Teofili L; Leone G; Michiels JJ
    Semin Thromb Hemost; 1997; 23(5):411-8. PubMed ID: 9387199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.
    De Stefano V; Vannucchi AM; Ruggeri M; Cervantes F; Alvarez-Larrán A; Iurlo A; Randi ML; Pieri L; Rossi E; Guglielmelli P; Betti S; Elli E; Finazzi MC; Finazzi G; Zetterberg E; Vianelli N; Gaidano G; Nichele I; Cattaneo D; Palova M; Ellis MH; Cacciola E; Tieghi A; Hernandez-Boluda JC; Pungolino E; Specchia G; Rapezzi D; Forcina A; Musolino C; Carobbio A; Griesshammer M; Barbui T
    Blood Cancer J; 2016 Nov; 6(11):e493. PubMed ID: 27813534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of venous thromboembolism in myeloproliferative neoplasms.
    Barbui T; De Stefano V
    Curr Opin Hematol; 2017 Mar; 24(2):108-114. PubMed ID: 27875375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms.
    Castelli R; Berzuini A; Manetti R; Delitala AP; Castro D; Sanna G; Sircana MC; Profili NI; Bartoli A; La Cava L; Lambertenghi Deliliers G; Donadoni M; Gidaro A
    Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
    Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
    Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Visceral Vein Thrombosis of Myeloproliferative Neoplasm --Review].
    Zhang X; Yang J; Hao HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1627-1630. PubMed ID: 36208278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
    Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
    Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey.
    Ellis MH; Lavi N; Vannucchi A; Harrison C
    Thromb Res; 2014 Aug; 134(2):251-4. PubMed ID: 24842684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
    De Stefano V; Finazzi G; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):65. PubMed ID: 29946112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses.
    Debureaux PE; Cassinat B; Soret-Dulphy J; Mora B; Verger E; Maslah N; Plessier A; Rautou PE; Ollivier-Hourman I; De Ledinghen V; Goria O; Bureau C; Siracusa C; Valla D; Giraudier S; Passamonti F; Kiladjian JJ
    Blood Adv; 2020 Aug; 4(15):3708-3715. PubMed ID: 32777065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies.
    Kiladjian JJ; Cassinat B
    Am J Hematol; 2023 May; 98(5):794-800. PubMed ID: 36869873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.